Biotech MannKind (NAS: MNKD) , which is developing the inhalable insulin product Afrezza, released its third-quarter earnings report after the market closed on Thursday. There were several key updates regarding the company's financial situation and cash burn.
In the following video, health-care analysts Max Macaluso and David Williamson discuss these results and a few issues investors need to watch.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Is MannKind Back on Track? originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.